IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

A RCTO TE application of

 $^{
m OV}$ Tohr $_{
m I}$ UEDA et al.

l No. 08/081,183

Group Art Unit 1803

led June 25, 1993

Examiner J. Wilson

PYRIMIDINE 2'-METHYLIDENE NUCLEOSIDE COMPOUNDS

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT

ACCOUNT NO. 23-0975.

Do Not

RESPONSE

Honorable Commissioner of Patents and Trademarks, Washington, D.C.

sir:

In response to the Official Action dated June 1, 1994, the period for response having been extended for two months by the attached petition, please amend the present application as follows:

IN THE SPECIFICATION:

Page 1, line 8 from the bottom, rewrite as:

B1

--developed novel compounds useful as [anticancer] antitumor and anti-viral [agent] agents and found that pyrimidine
2'-methylidine--.

IN THE ABSTRACT OF THE DISCLOSURE:

Please rewrite the bottom two lines as follows:

Ba

--activities, thus providing novel [anticancer] <u>antitumor</u> and anti-viral [agent] <u>agents</u>--.

REMARKS

Undersigned acknowledges with appreciation the helpful personal interview with Examiner Wilson on October 26, 1994.

No specific agreements were reached at said interview, however, it is believed that prosecution was significantly advanced by this interview.

The representations made at said interview are incorporated in the remarks below.

With regard to the Abstract of the Disclosure, the required correction has been made.

....